Phase 2, Phase 3 Recruiting Network
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in District of Columbia: - Kaiser Permanente-Capitol Hill Medical Center — Washington D.C., District of Columbia
Phase 3 Recruiting Academic/Other
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06632327
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- MedStar Washington Hospital Center — Washington D.C., District of Columbia
Phase 3 Recruiting Network
This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastase…
Sponsor: Children's Oncology Group
NCT ID: NCT05235165
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 3 Recruiting Industry
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if ol…
Sponsor: Eli Lilly and Company
NCT ID: NCT06890598
Sites in District of Columbia: - Sibley Memorial Hospital — Washington D.C., District of Columbia
Phase 3 Recruiting Academic/Other
This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…
Sponsor: NRG Oncology
NCT ID: NCT06500481
Sites in District of Columbia: - Sibley Memorial Hospital — Washington D.C., District of Columbia
Phase 3 Recruiting Industry
TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without actionable gen…
Sponsor: AstraZeneca
NCT ID: NCT07291037
Sites in District of Columbia: - Research Site — Washington D.C., District of Columbia
Phase 3 Recruiting Industry
The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas a first-line therapy in participants with locally advanced o…
Sponsor: AstraZeneca
NCT ID: NCT06350097
Sites in District of Columbia: - Research Site — Washington D.C., District of Columbia
Phase 3 Recruiting Industry
This study is open to adults 18 years and older who have early-stage non-small cell lung cancer (NSCLC). Their cancer must have a specific change in a gene called HER2. Genes provide the instructions for making proteins, and this change le…
Sponsor: Boehringer Ingelheim
NCT ID: NCT07195695
Sites in District of Columbia: - George Washington University Cancer Center — Washington D.C., District of Columbia
Phase 3 Recruiting Academic/Other
Primary Objective To compare two smoking cessation interventions among individuals undergoing lung cancer screening. Primary outcomes are: 3-month self-reported abstinence from cigarettes and 6-month self-reported and bioverified abstinenc…
Sponsor: Georgetown University
NCT ID: NCT06290869
Sites in District of Columbia: - Georgetown University Medical Center — Washington D.C., District of Columbia
Phase 2 Recruiting Network
This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tis…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05642572
Sites in District of Columbia: - Kaiser Permanente-Capitol Hill Medical Center — Washington D.C., District of Columbia
Phase 2 Recruiting NIH
This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back after a period of improvement (recurrent). Osimertinib …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03191149
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
Phase 2 Recruiting Industry
The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-smal…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06667076
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- Washington DC VA Medical Center — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in District of Columbia: - Local Institution - 2106 — Washington D.C., District of Columbia
- Local Institution - 2110 — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in District of Columbia: - Washington Cancer Institute at MedStar Washington Hospital Center — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Industry
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each othe…
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06162221
Sites in District of Columbia: - Georgetown University Medical Center — Washington D.C., District of Columbia
Phase 2 Recruiting Federal
This study is a multicenter Phase II single arm trial to assess the safety and efficacy of chemotherapy and immunotherapy followed by radiotherapy in patients with unresectable Stage III NSCLC.
Sponsor: VA Office of Research and Development
NCT ID: NCT06275360
Sites in District of Columbia: - VA Central Office, Washington, DC — Washington D.C., District of Columbia
Phase 2 Recruiting Academic/Other
This is a phase II trial of durvalumab and tremelimumab in combination of platinum-based chemotherapy. Patients with stage IV Non-Small-Cell-Lung Cancer (NSCLC) with human immunodeficiency virus (HIV) infection will be eligible. Patients w…
Sponsor: Georgetown University
NCT ID: NCT04499053
Sites in District of Columbia: - Georgetown Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia
- Medstar Washington Hospital Center — Washington D.C., District of Columbia
Phase 2 Recruiting Academic/Other
This clinical trial plans to assess to what extent the on-treatment circulating tumor DNA (ctDNA) can predict the subset of patients with NSCLC who will respond to immunotherapy treatment only and which patients will need both immunotherap…
Sponsor: Hackensack Meridian Health
NCT ID: NCT05715229
Sites in District of Columbia: - Lombardi Comprehensive Cancer Center, Georgetown University — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to investigate the safety, the activity of VERT-002 (PFL-002), and the optimal safe dose to be used, in participants with solid tumors including non-small cell lung cancer.
Sponsor: Pierre Fabre Medicament
NCT ID: NCT06669117
Sites in District of Columbia: - Georgetown Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia
Phase 1 Recruiting Industry
The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose. This study is seeking participants who have…
Sponsor: Pfizer
NCT ID: NCT06447662
Sites in District of Columbia: - Sibley Memorial Hospital — Washington D.C., District of Columbia
Phase 1 Recruiting Industry
The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The s…
Sponsor: Eli Lilly and Company
NCT ID: NCT06586515
Sites in District of Columbia: - Sibley Memorial Hospital — Washington D.C., District of Columbia
Recruiting Academic/Other
This study will evaluate if a direct-to-patient, de-centralized, remote approach will improve clinical research outreach and engagement for patients with SCLC, in the context of a bio-specimen collection study. The study will also assess s…
Sponsor: Addario Lung Cancer Medical Institute
NCT ID: NCT06486428
Sites in District of Columbia: - Https://Alcmi.Org/Clinical-Trials/Current-Studies/Succeed-Study.Html — Multiple Locations, District of Columbia
NA Recruiting Network
This clinical trial evaluates the usefulness of using a smartphone-based HIV-specific smoking cessation intervention at the time of lung cancer screening in helping people living with HIV quit smoking. Positively Smoke Free - Mobile may he…
Sponsor: AIDS Malignancy Consortium
NCT ID: NCT04949464
Sites in District of Columbia: - George Washington University — Washington D.C., District of Columbia